Optimizing Medicine Development for Real-World Efficacy in Patients: A Biopsychosocial Approach
It's estimated that only 20% of health outcomes are due to clinical care, with the remaining 80% as a result of social determinants of health. Medicine development leaders must understand the broader context of patient lives in order to create therapies with real-world efficacy.
Summary:
It's estimated that only 20% of health outcomes are due to clinical care, with the remaining 80% as a result of social determinants of health. Medicine development leaders must understand the broader context of patient lives in order to create therapies with real-world efficacy.
In this podcast, Noël Theodosiou tells us how she's working with life science companies, to understand and contextualize the real world that patients live in to create therapeutics that fit in the environment to deliver actual impact.
Noël argues that taking an approach that combines biology, psychology and sociology provides companies with decision-making capabilities that connects good business practices with life science's social contracts with patients.
For more information about Luminous, visit LuminousEffect.com.
For more information about Patients as Partners in Clinical Research, visit PatientsAsPartnersConference.com.
Related Podcasts
View All
Incorporating Quantitative Values of Patient Perspectives into Clinical Trial Design
Strategies to Empower Clinical Sites, Streamline Trials and Enhance Patient Care
Astellas’ Head of Patient Centricity on his New Book "A Bandana and a Bluebird," and Lessons from Patients for Medicine Development
